Topics

TIM-3 Inhibition Enhances CAR-T Function

Cancer Immunotherapy Cellular Stress Tumor Microenvironment Intercellular Communication & Diseases

TIM-3, encoded by HAVCR2, is an inhibitory and context-dependent immune receptor associated with chronically stimulated T cells. CAR-T products that repeatedly encounter antigen can upregulate TIM-3 alongside PD-1, LAG-3, and other exhaustion markers, prompting efforts to block the receptor or rewire its signaling. The evidence is strongest in preclinical systems: a TIM-3/CD28 switch receptor improved CAR-T persistence and antitumor efficacy, a small-molecule inhibitor enhanced T-cell-mediated control in mouse models, and an engineered TIM-3-Fc decoy strengthened CD19 CAR-T activity in B-cell acute lymphoblastic leukemia models. These studies support a tractable pathway, but they do not yet establish TIM-3 inhibition as a standard clinical CAR-T enhancement Its expression is also found on other immune populations, so a systemic intervention can reshape the microenvironment beyond the engineered T-cell compartment[1][2][3].

TIM-3 interacts with ligands that include galectin-9 and participates in signaling shaped by cellular activation, ligand context, and receptor-associated proteins. During persistent stimulation, its expression can mark reduced cytokine production, proliferation, and cytotoxic capacity. Direct blockade may interrupt inhibitory signaling, whereas a decoy sequesters ligands before they engage cell-surface TIM-3. The T3/28 switch receptor takes a more active approach by coupling an extracellular TIM-3 recognition module to CD28 costimulation, converting an inhibitory environmental cue into a productive signal. These formats are not mechanistically equivalent, and their efficacy can depend on ligand density, co-expressed checkpoints, antigen burden, and the differentiation state of the CAR-T population The desired outcome is not continuous maximal signaling, but renewed responsiveness during repeated encounters without erasing homeostatic restraint after antigen clears[1][2][3].

Potential applications include hematologic malignancies with repeated antigen exposure and solid tumors rich in TIM-3 ligands. A secreted decoy or cell-restricted switch receptor could concentrate activity near engineered T cells and reduce the systemic exposure of an antibody. Small molecules offer adjustable dosing but may affect multiple immune populations or pathways. Combination with PD-1 blockade is biologically plausible because exhaustion networks are redundant, yet simultaneous checkpoint release can increase inflammatory toxicity and may push cells toward terminal activation. Product development should measure repeated killing, persistence, cytokine output, and tumor control rather than treating a fall in TIM-3 staining as sufficient evidence of restored function Disease models should include low and high ligand settings because a design may appear inactive simply when its environmental trigger is absent[1][2].

Translation requires clearer receptor biology and rigorous safety comparisons among blockade, decoy, switch, and gene-disruption strategies. Human tumor samples should establish which ligands are available and whether TIM-3 marks a reversible progenitor population or terminally dysfunctional cells. Inducible expression could limit exposure if unregulated costimulation proves hazardous. Trials need matched controls and pharmacodynamic evidence that the engineered pathway changes CAR-T state in vivo. Long-term follow-up should evaluate autoimmunity, clonal expansion, and loss of activation control. TIM-3 inhibition can improve CAR-T function in carefully designed experimental systems, but clinical value will depend on selecting a ligand-rich, checkpoint-dependent context and preserving the normal brakes that protect against excessive immunity Comparative studies should retain identical CAR architecture and manufacturing so that any improvement can be attributed to the TIM-3 modification itself[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L264 DNA Damage Repair Inhibitor Library
DNA damage response (DDR) is a fundamental mechanism for maintaining genomic stability. When DNA damage occurs, such as single- or double-strand breaks or replication fork stalling, cells rely on key proteins including ATM, ATR, PARP, and DNA-PK to sense the damage and transmit signals, thereby regulating DNA repair, cell-cycle arrest, and cell death. Inhibition of specific DNA repair or checkpoint pathways can prevent tumor cells from effectively repairing accumulated DNA damage, ultimately leading to tumor cell death. MCE DNA Damage Repair Inhibitor Library contains 1,544 compounds, focusing on key nodes involved in DNA damage response and DNA repair. The library covers multiple DNA repair and cell-cycle checkpoint pathways, providing a systematic compound screening tool for research on precision oncology, synthetic lethality, drug resistance mechanisms, and chemo- or radiosensitization.
83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-114409 GB1107
GB1107 is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with a Kd of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model.
Galectin  
Cancer   Lung Fibrosis  
20
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-19756 OTX008
OTX008 is a selective inhibitor of galectin-1.
Galectin  
Cancer  
18
HY-19940 Olitigaltin
Olitigaltin (TD139) is a high-affinity Galectin-3 inhibitor with a Kd value of 14 nM. Olitigaltin inhibits the activity of the AKT/β-catenin pathway, induces Apoptosis, and downregulates SREBP1 expression. Olitigaltin enhances the phosphorylation level of ERK. Olitigaltin alleviates bleomycin (HY-17565A)-induced advanced pulmonary fibrosis in mice. Olitigaltin delays the onset of diabetes, and improves glucose tolerance and serum insulin levels. Olitigaltin alleviates liver injury. Olitigaltin maintains the structure of hippocampal excitatory synapses, restores γ-wave power in the hippocampal CA1 region, inhibits hippocampal neuroinflammation, and improves cognitive function in neuroinflammation models. Olitigaltin can be used in research related to thyroid cancer, idiopathic pulmonary fibrosis, type 1 diabetes, hepatitis, and cognitive dysfunction induced by neuroinflammation.
Galectin   Akt   β-catenin   Apoptosis   ERK  
Neurological, Eye or Ear Disease   Thyroid Cancer   Liver Disease   Type 1 Diabetes   Lung Fibrosis  
13
HY-148905 p-Aminophenylmercuric acetate
p-Aminophenylmercuric acetate is an organomercurial activator of matrix metalloproteinases (MMP). P-Aminophenylmercuric acetate participates in the activation and inhibition of MMP-8 by attacking protein sulfhydryl or inducing cysteine switching reaction. p-Aminophenylmercuric acetate promotes the shedding of betacellulin precursor (pro-BTC). p-Aminophenylmercuric acetate influences the binding of agonists and antagonists to the opiate receptor.
Cathepsin   MMP  
Infection  
11
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-130208 Thiodigalactoside
Thiodigalactoside (TDG) is an orally active and potent galectin (GAL) inhibitor with Kd values of 24 μM, 49 μM for GAL1 and GAL3, respectively. Thiodigalactoside, a non-metabolizable disaccharide, has anti-inflammatory and anti-cancer activity. Thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats.
Galectin  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
5
HY-P70535 Galectin-9/LGALS9 Protein, Human (HEK293, His)
Galectin-9/LGALS9 Protein acts as an eosinophil chemoattractant, recruiting and migrating eosinophils, key immune cells in inflammatory responses. It also serves as an angiogenesis inhibitor, regulating blood vessel formation and impacting vascular processes. Functioning as a regulatory modulator, Galectin-9/LGALS9 suppresses interferon-gamma (IFNG) production by natural killer cells, exerting control over immune signaling pathways. Galectin-9/LGALS9 Protein, Human (HEK293, His) is the recombinant human-derived Galectin-9/LGALS9 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins Inhibitory Checkpoint Molecules Galectin-9

4
HY-P9963 Blinatumomab
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia.

Species: Human

CD19  
Cancer  
3
HY-P72637 Galectin-9/LGALS9 Protein, Mouse (GST)
The Galectin-9/LGALS9 protein is an eosinophil chemoattractant that directs the migration of eosinophils, key immune cells in the inflammatory response.It also acts as an angiogenesis inhibitor, regulating blood vessel formation.Galectin-9/LGALS9 Protein, Mouse (GST) is the recombinant mouse-derived Galectin-9/LGALS9 protein, expressed by E.coli , with N-GST labeled tag.

Species: Mouse; Source: E. coli

Immune Checkpoint Proteins Inhibitory Checkpoint Molecules Galectin-9

3
HY-P990587 FR104
FR104 is a humanized antibody expressed in CHO cells that targets CD28. FR104 comprises a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.08 kDa. The isotype control for FR104 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).

Species: Human

CD28  
Inflammation or Immune System Disease  
2
HY-P99123 Anti-Mouse CD28 Antibody (37.51)
Anti-Mouse CD28 Antibody (37.51) is an agonistic agonistic CD28-specific antibody derived from the host Syrian Hamster. Anti-Mouse CD28 Antibody (37.51) partially prevents lethal graft-versus-hostdisease (GVHD) by selective depletion of alloreactive T cells in mice.

Species: Mouse

CD28  
Inflammation or Immune System Disease  
2
HY-P99711 Loncastuximab
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349).

Species: Human

CD19   ADC Antibodies  
Cancer  
2
HY-144987 RBN013209
RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD+ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors.
CD38   LAG-3   Tim3   PD-1/PD-L1  
Inflammation or Immune System Disease   Lung Cancer   Breast Cancer  
1
HY-P99420 Acazicolcept
Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities.
CD28  
Inflammation or Immune System Disease  
1
HY-P99285 Denintuzumab
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia.

Species: Human

ADC Antibodies   CD19  
Leukemia/Lymphoma/Myeloma  
1
HY-P99293 Galiximab
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors.

Species: Human

CD28   Apoptosis  
Cancer  
1
HY-153084A CD19 CAR mRNA (Human)
CD19 CAR mRNA (Human) expresses CAR protein that specifically targets human CD19. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia.
mRNA   CD19  
Cancer  
1
HY-P99302 Lulizumab
Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft.

Species: Human

CD28  
Inflammation or Immune System Disease  
1
HY-147041 Selvigaltin
Selvigaltin (GB1211) is an orally active galectin-3 small molecule inhibitor with an IC50 value of 12 nM in rabbits, showing anti-tumor activity. Selvigaltin decreases galectin-3 levels in the liver and reduces biomarkers of liver function (AST, ALT, bilirubin), inflammation (cells foci) and fibrosis (PSR, SHG), as well as decreasing the mRNA and protein expression of several key inflammation and fibrosis biomarkers (IL6, TGFβ3, SNAI2, collagen). Selvigaltin restores T-cell activity and induces less tumors and metastasis.
Galectin  
Inflammation or Immune System Disease  
1
HY-P99044 Sabatolimab
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells.

Species: Human

Tim3  
Inflammation or Immune System Disease   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer  
1
HY-P99117 Cadonilimab
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

Species: Human

PD-1/PD-L1   CTLA-4  
Inflammation or Immune System Disease   Gastric Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P99113 Inebilizumab
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.

Species: Human

ADC Antibodies   CD19  
Myasthenia gravis   Multiple Sclerosis  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P81703 TIM3 Antibody (YA1448)
TIM3 Antibody (YA1448) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to TIM3.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

1
HY-P990304B Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1)
Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) is a mouse-derived IgG1 κ antibody inhibitor that targets mouse 4-1BBL/CD137L. Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) is a chimeric version of the original TKS-1 antibody (HY-P990304). The variable domain sequences are identical to the original TKS-1 but the constant region sequences have been switched from rat IgG2a to mouse IgG1. Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) reacts with mouse 4-1BB ligand (4-1BBL). Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) can be used for the researches of cancer, infection, inflammation and immunology.

Species: Mouse

TNF Receptor  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-P992178 ALLO-647
ALLO-647 is a human monoclonal antibody targeting CD52. ALLO-647 transiently and selectively depletes host lymphocytes to promote the proliferation of allogeneic CAR T-cell following infusion. ALLO-647 can be used for the research of B-cell lymphoma and follicular lymphoma.

Species: Human

NF-κB  
Leukemia/Lymphoma/Myeloma  
/
HY-P990270 Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1)
Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse CD40L/CD154. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) is a chimeric version of the original MR-1 antibody (HY-P990134). The variable domain sequences are identical to the original MR-1 but the constant region sequences have been switched from Armenian hamster IgG to mouse IgG1. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) blocks CD40/CD40L signaling. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) can be used for researches of cancer, inflammation and immunology.

Species: Mouse

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P991397 Sym023
Sym023 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. Sym023 enhances immunostimulatory and anti-tumor activities. Sym023 can be used in Non-small cell lung cancer, Solid tumors and Lymphoma research.

Species: Human

Tim3  
Cancer  
/
HY-P11129 MAGE-A4 (286-294)
MAGE-A4 (286-294) is a polypeptide derived from the 286th to 294th amino acids of the MAGE-A4 protein. MAGE-A4 (286-294) binds HLA-­A*02 with an affinity of 560.08 nM and an IC50 of 8.52 nM. MAGE-A4 (286-294) can be detected in various types of cancers (such as esophageal cancer, lung squamous cell carcinoma, bladder cancer). MAGE-A4 (286-294) can be used to produce CAR-T cells and to develop CAR-T cell therapy.
Others  
Cancer  
/
HY-P992511 CS2009
CS2009 is a trispecific antibody targeting PD-1, CTLA-4 and VEGFA. CS2009 blocks the interactions of PD-1/PD-L1, CTLA-4/CD80 and VEGFA/VEGFR2, mediates checkpoint inhibition, and suppresses tumor angiogenesis. CS2009 reactivates PD-1/CTLA-4 double-positive tumor-infiltrating T lymphocytes, induces T cell activation, enhances tumor growth inhibition, promotes vascular normalization, improves T lymphocyte infiltration, and converts the immunosuppressive tumor microenvironment into an immunocompetent one. CS2009 can be used for the research of various advanced solid tumors.

Species: Human

PD-1/PD-L1   CTLA-4   VEGFR  
Cancer  
/
HY-P991395 TQB2618
TQB2618 is a human IgG4 monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. TQB2618 activates immune cell function and induces significant anti-tumor activity when used in combination with anti-PD-1 agents.

Species: Human

Tim3  
Cancer  
/
HY-141432G NX-1607 (GMP)
NX-1607 (Cbl-b-IN-3) (GMP) is a GMP-grade NX-1607 (HY-141432). GMP-grade small molecules can be used as adjuvant agents in cell therapy. NX-1607 (GMP) enhances antigen recall, reduces T cell exhaustion and increases cytokine production. NX-1607 is an inhibitor of Cbl-b (an E3 enzyme).
E1/E2/E3 Enzyme  
Cancer   Inflammation or Immune System Disease  
/
HY-P990304C Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1)
Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) is a mouse-derived IgG2a κ antibody inhibitor that targets mouse 4-1BBL/CD137L.Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) is a chimeric version of the original TKS-1 antibody (HY-P990304). The variable domain sequences are identical to the original TKS-1 but the constant region sequences have been switched from rat IgG2a to mouse IgG2a. Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) reacts with mouse 4-1BB ligand (4-1BBL). Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) can be used for the researches of cancer, infection, inflammation and immunology.

Species: Mouse

TNF Receptor  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-P11108A RP-182 acetate
RP-182 acetate is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (Kd = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 acetate induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206high TAMs. RP-182 acetate has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 acetate is used in pancreatic cancer and melanoma research.
NF-κB   Apoptosis   TNF Receptor   Caspase  
Cancer   Inflammation or Immune System Disease  
/
HY-P990269 Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1)
Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD40L/CD154. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a chimeric version of the original MR-1 antibody (HY-P990134). The variable domain sequences are identical to the original MR-1 but the constant region sequences have been switched from Armenian hamster IgG to mouse IgG2a. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) blocks CD40/CD40L signaling. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) can be used for researches of cancer, inflammation and immunology.

Species: Mouse

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P990172 Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) can be used for the research of cancer.

Species: Mouse

PD-1/PD-L1  
Cancer  
/
HY-P991396 LY-3321367
LY-3321367 is a humanized IgG1 monoclonal antibody targeting TIM-3. LY-3321367 partially blocks the formation of the TIM-3/GAL-9 complex, completely blocks the binding of TIM-3 to phosphatidylserine, but does not block the formation of the TIM-3/CEACAM-1 complex. LY-3321367 is applicable to research related to various solid tumors, such as small cell lung cancer.

Species: Human

Tim3  
Small Cell Lung Cancer  
/
HY-P990870 Anti-CD19 Antibody (4G7)
Anti-CD19 Antibody (4G7) is an anti-human CD19 IgG1 monoclonal antibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977).

Species: Mouse

CD19   IFNAR   Interleukin Related  
Inflammation or Immune System Disease  
/
HY-P99027 Ieramilimab
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors.

Species: Human

LAG-3  
Triple-Negative Breast Cancer  
/
HY-P99895 Rulonilimab
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity.

Species: Human

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
/
HY-P99825 Relfovetmab
Relfovetmab is a monoclonal antibody and also serves as a single-chain variable fragment component for engineering chimeric antigen receptors (CAR) in modified CAR-T cells. Relfovetmab can be used in studies of cancer and immune disorders.

Species: Feline

Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P990704 Rilvegostomig
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.

Species: Human

PD-1/PD-L1   Transmembrane Glycoprotein  
Non-Small Cell Lung Cancer   Endometrial Cancer  
/
HY-P11108 RP-182
RP-182 is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (Kd = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206high TAMs. RP-182 has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 is used in pancreatic cancer and melanoma research.
NF-κB   Apoptosis   TNF Receptor   Caspase  
Inflammation or Immune System Disease  
/
HY-P990120 Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5)
Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) is an anti-rat Kappa Immunoglobulin Light Chain IgG2a monoclonal antibody. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance B cell depletion. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance T cell exhaustion after the injection of CD4 mAb (HY-P990792) and CD8 mAb (HY-P99129). Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can be used for research on immunology.

Species: Rat

Others  
Inflammation or Immune System Disease  
/
HY-P991198 M6903
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers.

Species: Human

Tim3  
Cancer  
/
HY-P99962 Surzebiclimab
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer.

Species: Human

Mucin  
Cancer  
/
HY-159884 MG-T-19
MG-T-19 is a potent small-molecule inhibitor targeting human TIM-3. MG-T-19 blocks the interactions between TIM-3 and its ligands such as phosphatidylserine, CEACAM1 and Galectin-9. MG-T-19 promotes the secretion of TNF-α and IFN-γ by peripheral blood mononuclear cells, and significantly enhances their ability to inhibit cancer cell proliferation. MG-T-19 can be used in studies related to acute myeloid leukemia.
Tim3   TNF Receptor   IFNAR  
Acute Myeloid Leukemia  
/
HY-N0600 Ginsenoside F3
Ginsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a Kd value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of IL‑2 and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer.
Interleukin Related   IFNAR   NF-κB  
Digestive System Disease   Cancer Immunology   Digestive System Inflammation  
/
HY-P991449 LY3415244
LY3415244 is a bispecific antibody that targets and inhibits TIM-3 and PD-L1. LY3415244 blocks the interaction between TIM-3 on immune cells and PD-L1 on the surface of tumor cells, establishes intercellular connections between TIM-3-positive immune cells and PD-L1-positive tumor cells, and blocks dual immunosuppressive signals. LY3415244 alleviates T cell exhaustion and restores T cell proliferation. LY3415244 induces broad-spectrum anti-drug antibodies, which impairs the binding capacity to soluble TIM-3 targets. LY3415244 can be used in research related to various advanced solid tumors.

Species: Human

PD-1/PD-L1   Tim3  
Cancer  
/
HY-P990171 Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG2a. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) can be used for the research of cancer.

Species: Mouse

PD-1/PD-L1  
Cancer  
/
HY-P990004 Anti-Mouse TIM-3 Antibody (B8.2C12)
Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 IgG1 monoclonal antibody. Anti-Mouse TIM-3 Antibody (B8.2C12) can block the binding of Tim-3 with Phosphatidylserine (PtdSer) and CEACAM1 without interfering with the binding to Galectin-9. Anti-Mouse TIM-3 Antibody (B8.2C12) can inhibit tumor growth and activate tumor infiltrating CD8+ T cells. Anti-Mouse TIM-3 Antibody (B8.2C12) can be used for studying cancer such as breast cancer and colon cancer and constructing experimental autoimmune encephalomyelitis (EAE) models.

Species: Mouse

Tim3  
Breast Cancer   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
/
HY-P990821 Anti-Mouse TIM-3 Antibody (RMT3-23)
Anti-Mouse TIM-3 Antibody (RMT3-23) is a kind of rat-derived anti-mouse TIM-3 IgG2a antibody inhibitor. Anti-Mouse TIM-3 Antibody (RMT3-23) blocks Tim-3 binding to phosphatidylserine (PtdSer) and carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1). Anti-Mouse TIM-3 Antibody (RMT3-23) inhibits phagocytosis of apoptotic cells in peritoneal exudate Mac1+ cells. Anti-Mouse TIM-3 Antibody (RMT3-23) can be used for the researches of inflammation and immunology, such as rheumatoid arthritis.

Species: Mouse

Tim3  
Inflammation or Immune System Disease  
/
HY-122822 GSK699
GSK699 is a KAT2A/B/PCAF/GCN5 PROTAC degrader. GSK699 induces proteasome-dependent degradation of KAT2A, KAT2B, PCAF and GCN5, regulates the histone acetyltransferase activity of the SAGA complex, and reduces the level of histone H3K9ac. GSK699 inhibits the growth of neuroblastoma, acute myeloid leukemia and small cell lung cancer cells. GSK699 reduces the production of inflammatory cytokines and chemokines, and impairs LPS-stimulated immune cell responses. GSK699 is applicable to research related to acute myeloid leukemia, small cell lung cancer, neuroblastoma and inflammatory diseases.
PROTACs   Histone Acetyltransferase   Interleukin Related   CXCR   TNF Receptor   CD28  
Inflammation or Immune System Disease   Small Cell Lung Cancer   Acute Myeloid Leukemia  
/
HY-P990242 Anti-Mouse Galectin-9 Antibody (RG9-1)
Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4+ and CD8+ T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia.

Species: Mouse

Galectin   TNF Receptor   IFNAR   Interleukin Related  
Inflammation or Immune System Disease   Breast Cancer  
/
HY-N2907 Atranorin
Atranorin is a secondary metabolite of lichens and AKT inhibitor. Atranorin possesses multiple activities such as antibacterial, anti-inflammatory, antioxidant, anti-glycation, analgesic, and anti-tumor effects. Atranorin has IC50 values for scavenging DPPH and ABTS free radicals of 117 μM and less than 10 μM, respectively. Additionally, Atranorin also exhibits effects in promoting wound healing. Atranorin can be used in the research of various diseases, including myelodysplastic syndromes, tumors, and inflammatory conditions.
Free Radical Scavengers   Wnt   Ras   Endogenous Metabolite   Bacterial   Fungal   PD-1/PD-L1   Tim3   Akt   AP-1   STAT  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Bacterial Infection   Fungal Infection   Pain   Digestive System Inflammation   Hypertension   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
/
HY-W150340 β-Lactose
β-Lactose is a disaccharide commonly found in milk and dairy products. It consists of two monosaccharides, glucose and galactose, linked by β-glycosidic bonds. β-Lactose has various applications in the food industry, especially as a sweetener and bulking agent. Furthermore, it can be used as a substrate for enzymes involved in lactose metabolism and as a model compound for studying carbohydrate-protein interactions.
Galectin   Biochemical Assay Reagents  
Cancer  
/
HY-P99961 Tifcemalimab
Tifcemalimab (JS004; Icatolimab) is a humanized IgG4 monoclonal antibody against BTLA (B and T lymphocyte attenuator). By binding to BTLA, tifcemalimab blocks the interaction of HVEM-BTLA, thereby inhibiting the BTLA-mediated inhibitory signaling pathway. Tifcemalimab can be used in research related to squamous cell non-small cell lung cancer.

Species: Human

CD28  
Non-Small Cell Lung Cancer  
/
HY-P990865 Anti-CD28 Antibody (9.3)
Anti-CD28 Antibody (9.3) is an anti-human CD28 IgG2a monoclonal antibody. Anti-CD28 Antibody (9.3) can activate T cells. Anti-CD28 Antibody (9.3) can be used for research on immunology. The recommend isotype control of Anti-CD28 Antibody (9.3): Mouse IgG2a kappa, Isotype Control (HY-P99978).

Species: Human

CD28  
Inflammation or Immune System Disease  
/
HY-155175 TIM-3-IN-2
TIM-3-IN-2 is a TIM-3 inhibitor. TIM-3-IN-2 blocks the interactions of TIM-3 with PtdSer, CEACAM1 and Gal-9, and inhibits the immunosuppressive function of TIM-3. TIM-3-IN-2 restores IFNγ release from peripheral blood mononuclear cells. TIM-3-IN-2 inhibits the proliferation of acute myeloid leukemia cells. TIM-3-IN-2 can be used for the research of acute myeloid leukemia.
Tim3   IFNAR  
Acute Myeloid Leukemia  
/
HY-P99827 Cobolimab
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC).

Species: Human

Tim3  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-126854 N-Acetyllactosamine
N-Acetyllactosamine (N-Acetyl-D-lactosamine), a nitrogen-containing disaccharide, is a galectin-3 inhibitor, which is an important component of various oligosaccharides such as glycoproteins and sialyl Lewis X. N-Acetyllactosamine can be used as the starting material for the synthesis of various oligosaccharides. N-Acetyllactosamine has prebiotic effects.

Source: Escherichia coli strains and Corynebacterium ammoniagenes

Endogenous Metabolite   Galectin  
Cardiovascular Disease   Lung Fibrosis  
/
HY-P99976 Anti-Mouse CD19 Antibody (1D3)
Anti-Mouse CD19 Antibody (1D3) is an IgG2a antibody inhibitor targeting mouse CD19. Anti-Mouse CD19 Antibody (1D3) reduces CD19 expression levels on the surface of B cells. Anti-Mouse CD19 Antibody (1D3) inhibits the replication of peritoneal B-1a cells.

Species: Mouse

CD19  
Inflammation or Immune System Disease  
/
HY-114440 Belapectin
Belapectin (GR-MD-02) is a Galectin-3 (Gal-3) inhibitor. Belapectin drives tumor-induced immunosuppression by inducing T cell Apoptosis. Belapectin promotes tumor regression and improves survival of tumor-bearing mice through a CD8+ T cell-dependent mechanism. Belapectin binds to Gal-3 with affinity Ki of 2.8 μM.
Galectin   Apoptosis  
/
HY-P99139 Anti-Mouse IL-1b Antibody (B122)
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure.

Species: Mouse

Interleukin Related   Reactive Oxygen Species (ROS)   Ferroptosis  
Blood or Cardio-cerebrovascular Disease   Glioma  
/
HY-P99113A Inebilizumab (FUT8-KO)
Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica.

Species: Human

CD19  
Multiple Sclerosis  
/
HY-128852 N-Acetyl-D-galactosamine, 98%
N-Acetyl-D-galactosamine (GalNAc) is a terminal essential amino sugar derived from galactose and forms the antigens of blood group A in humans. N-Acetyl-D-galactosamine (GalNAc) interact with Soya bean agglutinin (SBA), hence decreasing the effects of SBA on cellular membrane permeability and tight junction protein expression in piglets. N-Acetyl-D-galactosamine (GalNAc) inhibits the hemagglutinating activity by the lectin.
Galectin   Endogenous Metabolite  
/
HY-P99868 Duvortuxizumab
Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E.

Species: Human

CD19   CD3  
Cancer  
/
HY-P99761 Obexelimab
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus.

Species: Human

CD19   Apoptosis  
Inflammation or Immune System Disease  
/
HY-P9986 Tiragolumab
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma.

Species: Human

CD28  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-163028 ML-T7
ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research.
Tim3  
Cancer  
/
HY-P991028 Surovatamig
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma.

Species: Human

CD3   CD19   Interleukin Related   TNF Receptor   IFNAR  
Non-Hodgkin Lymphoma  
/
HY-P9975 Theralizumab
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis.

Species: Human

CD28  
Inflammation or Immune System Disease  
/
HY-P70696 Galectin-9/LGALS9 Protein, Human (GST)
Galectin-9/LGALS9 Protein acts as an eosinophil chemoattractant, recruiting and migrating eosinophils, key immune cells in inflammatory responses. It also serves as an angiogenesis inhibitor, regulating blood vessel formation and impacting vascular processes. Functioning as a regulatory modulator, Galectin-9/LGALS9 suppresses interferon-gamma (IFNG) production by natural killer cells, exerting control over immune signaling pathways. Galectin-9/LGALS9 Protein, Human (GST) is the recombinant human-derived Galectin-9/LGALS9 protein, expressed by E. coli , with N-GST labeled tag.

Species: Human; Source: E. coli

Immune Checkpoint Proteins Inhibitory Checkpoint Molecules Galectin-9

/
HY-P700082AF Animal-Free Galectin-9/LGALS9 Protein, Human (His)
Galectin-9/LGALS9 Protein acts as an eosinophil chemoattractant, recruiting and migrating eosinophils, key immune cells in inflammatory responses. It also serves as an angiogenesis inhibitor, regulating blood vessel formation and impacting vascular processes. Functioning as a regulatory modulator, Galectin-9/LGALS9 suppresses interferon-gamma (IFNG) production by natural killer cells, exerting control over immune signaling pathways. Animal-Free Galectin-9/LGALS9 Protein, Human (His) is the recombinant human-derived animal-FreeGalectin-9/LGALS9 protein, expressed by E. coli , with N-His labeled tag. This product is for cell culture use only.

Species: Human; Source: E. coli

Immune Checkpoint Proteins Animal-free Recombinant Proteins Inhibitory Checkpoint Molecules Galectin-9

/
HY-P78217 TIM-3/HAVCR2 Protein, Human (Biotinylated, HEK293, His-Avi)
The TIM-3/HAVCR2 protein regulates immune responses to pathogens, interacting with LGALS9 on infected macrophages to limit bacterial growth. It enhances CD8+ T cell responses and acts as a phosphatidylserine receptor, mediating phagocytosis of apoptotic cells. TIM-3/HAVCR2 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived TIM-3/HAVCR2 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins Biotinylated Proteins Inhibitory Checkpoint Molecules TIM-3

/
HY-P72448 TIM-3/HAVCR2 Protein, Mouse (HEK293, His)
The TIM-3/HAVCR2 protein is a cell surface receptor that regulates immune responses by inhibiting macrophage activation and suppressing Th1-mediated autoimmunity. TIM-3/HAVCR2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived TIM-3/HAVCR2 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins Inhibitory Checkpoint Molecules TIM-3

/
HY-P705214 Galectin-9/LGALS9 Protein, Human (Biotinylated, HEK293, His-Avi)
Galectin-9/LGALS9 Protein acts as an eosinophil chemoattractant, recruiting and migrating eosinophils, key immune cells in inflammatory responses. It also serves as an angiogenesis inhibitor, regulating blood vessel formation and impacting vascular processes. Functioning as a regulatory modulator, Galectin-9/LGALS9 suppresses interferon-gamma (IFNG) production by natural killer cells, exerting control over immune signaling pathways. Galectin-9/LGALS9, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived Galectin-9/LGALS9 protein, expressed by HEK293, with C-Avi;C-His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins Biotinylated Proteins Inhibitory Checkpoint Molecules Galectin-9

/
HY-P71995 TIM-3/HAVCR2 Protein, Mouse (HEK293, hFc)
The TIM-3/HAVCR2 protein is a cell surface receptor that regulates immune responses by inhibiting macrophage activation and suppressing Th1-mediated autoimmunity. TIM-3/HAVCR2 Protein, Mouse (HEK293, hFc) is the recombinant mouse-derived TIM-3/HAVCR2 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins Inhibitory Checkpoint Molecules TIM-3

/
HY-P70812 TIM-3/HAVCR2 Protein, Human (HEK293, Fc-His)
T cell immunoglobulin mucin-3 is an inhibitory receptor, and inhibits T cell functions. TIM-3 regulates immune responses in autoimmunity and cancer. TIM-3 has multiple different ligands: galectin 9, phosphatidylserine (PtdSer), CEACAM1 and HMGB1. The TIM-3-ligand axis is critical in the pathogenesis of numerous conditions, including autoimmune diseases, infections, cancers, transplant rejection, and chronic inflammation. TIM-3/HAVCR2 Protein, Human (HEK293, Fc-His) is the recombinant human-derived TIM-3/HAVCR2 protein, expressed by HEK293 , with C-hFc, C-6*His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins Inhibitory Checkpoint Molecules TIM-3

/
HY-P72419 TIM-3/HAVCR2 Protein, Human (Biotinylated, HEK293, Fc-Avi)
T cell immunoglobulin mucin-3 is an inhibitory receptor, and inhibits T cell functions. TIM-3 regulates immune responses in autoimmunity and cancer. TIM-3 has multiple different ligands: galectin 9, phosphatidylserine (PtdSer), CEACAM1 and HMGB1. The TIM-3-ligand axis is critical in the pathogenesis of numerous conditions, including autoimmune diseases, infections, cancers, transplant rejection, and chronic inflammation. TIM-3/HAVCR2 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived TIM-3/HAVCR2 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins Biotinylated Proteins Inhibitory Checkpoint Molecules TIM-3

/
HY-P72447 TIM-3/HAVCR2 Protein, Cynomolgus (HEK293, His)
The TIM-3/HAVCR2 protein is a cell surface receptor that regulates immune responses by inhibiting macrophage activation and suppressing Th1-mediated autoimmunity. TIM-3/HAVCR2 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived TIM-3/HAVCR2 protein, expressed by HEK293 , with N-8*His labeled tag.

Species: Cynomolgus; Source: HEK293

Immune Checkpoint Proteins Inhibitory Checkpoint Molecules TIM-3

/
HY-P72510 TIM-3/HAVCR2 Protein, Marmoset (HEK293, His)
TIM-3/HAVCR2 Protein is a transmembrane glycoprotein of the TIM family of immune regulating molecules and plays an important role in the Th1-mediated immune response. TIM-3/HAVCR2 Protein, Marmoset (HEK293, His) is the recombinant Marmoset-derived TIM-3/HAVCR2 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Marmoset; Source: HEK293

Immune Checkpoint Proteins Inhibitory Checkpoint Molecules TIM-3

/
HY-P704221 TIM-3/HAVCR2 Protein, Canie (HEK293, His)
TIM-3/HAVCR2 Protein, Canie (HEK293, His) is the recombinant canine-derived TIM-3/HAVCR2 protein, expressed by HEK293, with C-His tag.

Species: Canine; Source: HEK293

Immune Checkpoint Proteins Inhibitory Checkpoint Molecules TIM-3

/
HY-P704923 TIM-3/HAVCR2 Protein, Human (HEK293, mFc)

Species: Human; Source: HEK293

Immune Checkpoint Proteins Inhibitory Checkpoint Molecules TIM-3

/
HY-P705274 TIM-3/HAVCR2 Protein, Mouse (Biotinylated, HEK293, His-Avi)
The TIM-3/HAVCR2 protein is a cell surface receptor that regulates immune responses by inhibiting macrophage activation and suppressing Th1-mediated autoimmunity. TIM-3/HAVCR2, Mouse (Biotinylated, HEK293, His-Avi) is the recombinant mouse-derived TIM-3/HAVCR2 protein, expressed by HEK293, with N-Avi labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins Biotinylated Proteins Inhibitory Checkpoint Molecules TIM-3

/
HY-P81382 Galectin 9 Antibody (YA1127)
Galectin 9 Antibody (YA1127) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Galectin 9.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81382A Galectin 9 Antibody (YA1127)(PBS only)
Galectin 9 Antibody (YA1127) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Galectin 9.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85876 Galectin-9 Antibody (YA5568)
Galectin-9 Antibody (YA5568) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to Galectin-9.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P8F041A FITC-conjugated CD366(TIM-3) Antibody (F38-2E2)
FITC-conjugated CD366(TIM-3) Antibody (F38-2E2) is a Mouse-derived and FITC conjugated monoclonal antibody, targeting to CD366(TIM-3).

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F041B AF488-conjugated CD366(TIM-3) Antibody (F38-2E2)
AF488-conjugated CD366(TIM-3) Antibody (F38-2E2) is a Mouse-derived and AF488 conjugated monoclonal antibody, targeting to CD366(TIM-3).

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F041C PE-conjugated CD366(TIM-3) Antibody (F38-2E2)
PE-conjugated CD366(TIM-3) Antibody (F38-2E2) is a Mouse-derived and PE conjugated monoclonal antibody, targeting to CD366(TIM-3).

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F041F PerCP-conjugated CD366(TIM-3) Antibody (F38-2E2)
PerCP-conjugated CD366(TIM-3) Antibody (F38-2E2) is a Mouse-derived and PerCP conjugated monoclonal antibody, targeting to CD366(TIM-3).

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F041H AF647-conjugated CD366(TIM-3) Antibody (F38-2E2)
AF647-conjugated CD366(TIM-3) Antibody (F38-2E2) is a Mouse-derived and AF647 conjugated monoclonal antibody, targeting to CD366(TIM-3).

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P8F041I APC-conjugated CD366(TIM-3) Antibody (F38-2E2)
APC-conjugated CD366(TIM-3) Antibody (F38-2E2) is a Mouse-derived and APC conjugated monoclonal antibody, targeting to CD366(TIM-3).

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Conjugated Primary Antibodies Primary Antibodies

/
HY-P84683 TIM3 Antibody (YA4380)
TIM3 Antibody (YA4380) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to TIM3.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84683A TIM3 Antibody (YA4380)(PBS only)
TIM3 Antibody (YA4380) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to TIM3.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84991 TIM3 Antibody (YA4683)
TIM3 Antibody (YA4683) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to TIM3.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Nanobodies Primary Antibodies

/
HY-K2034 OptiLNP Antibody-ctLNP RNA Transfection Reagent (Human Primary T Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology and is specifically optimized for human primary T cells. It enables efficient and targeted RNA delivery, improving transfection efficiency in difficult-to-transfect primary T cells. The kit is ideally suited for applications including CAR-T and TCR-T cell engineering, cancer immunology research, immune cell engineering, and in vitro T cell functional studies.

Cell Biology Cell Culture Cell Transfection

/

Keywords

TIM-3 | CAR-T cells | T-cell exhaustion | checkpoint inhibition | switch receptor | galectin-9